Recent Clinical Trial Update



Recently, Roche released data from their halted study, Generation HD1, shedding light on promising insights regarding Tominersen, the drug under investigation. Despite the study’s abrupt halt in March 2021 due to safety concerns, subsequent analysis has revealed its potential positive impact on younger participants experiencing early symptoms of Huntington’s Disease.To delve deeper into these findings and gain a comprehensive understanding, we recommend reading an insightful article authored by Leora Fox from the Huntington’s Disease Society of America and Sarah Hernandez from the Hereditary Disease Foundation. This article not only provides a detailed exploration of the Generation HD1 data but also offers a comparison with Generation HD2 and discusses the importance of increased participation in clinical trials.

And that’s not all! Stay tuned for our February newsletter, where we’ll be detailing more on currently recruiting clinical trials in Australia. It’s an opportunity to stay informed and potentially contribute to groundbreaking research in the field of Huntington’s Disease. Don’t miss out on this valuable update!